Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Hodgkin Disease

Pathologic Complete Response, Rectal Neoplasms

Colorectal Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Esophageal Squamous Cell Carcinoma

Colorectal Neoplasms, Neoplasm, Residual

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Lymphoma, Follicular

Carcinoma, Hepatocellular

Advanced Solid Tumor

Nasopharyngeal Carcinoma

Carcinoma, Non-Small-Cell Lung

Nasopharyngeal Neoplasms

Squamous Cell Carcinoma of External Auditory Canal

Biliary Tract Neoplasms

Lymphatic Metastasis

Neoplasm Metastasis

Pseudomyxoma Peritonei

Locally Advanced Rectal Carcinoma

Esophageal Squamous Cell Carcinoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Hepatocellular, Liver Neoplasms

Head and Neck Neoplasms

Gastric Cancer Peritoneal Metastases

Colorectal Neoplasms

Muscle Invasive Bladder Cancer (MIBC)

Clinical Trials

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

HOVON164HL

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

TRIUNITE06

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

FMT-LUNG

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

ATARI-PDAC

Pseudovax

A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer

TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy

Endosurgery-02

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

FRONT-1

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

FUTURE

HARBOR